KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)
Q3-CY2026Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014
Balance Sheet Date2026-Apr-302026-Jan-312025-Oct-312025-Jul-312025-Apr-302025-Jan-31
Fiscal PeriodQ4-FY2026Q3-FY2026Q2-FY2026Q1-FY2026Q4-FY2025Q3-FY2025
Operating Cash Flow(18,720,000$)(18,366,000$)(18,343,000$)(26,274,000$)(24,056,000$)(17,997,000$)(18,056,000$)(17,499,000$)
Investing Cash Flow(172,706,000$)(14,919,000$)(7,420,000$)(8,232,000$)(7,404,000$)(4,450,000$)(4,420,000$)(7,034,000$)
Purchases of Property and Equipment9,664,000$9,797,000$7,265,000$8,166,000$7,389,000$4,063,000$4,447,000$7,037,000$
Financing Cash Flow(185,000$)149,182,000$(27,000$)(1,875,000$)214,703,000$(119,000$)(575,000$)116,253,000$
End Cash Position99,710,000$291,321,000$175,424,000$201,214,000$237,595,000$54,352,000$76,918,000$99,969,000$8,249,000$
Exchange Rate Effect
Dividends Paid
Unlevered Free Cash Flow(28,384,000$)(28,163,000$)(25,608,000$)(34,440,000$)(31,445,000$)(22,060,000$)(22,503,000$)(24,536,000$)